Last reviewed · How we verify
NCT04895007
Comparative Evaluation of Covid-19 Vaccines Response
trial testing Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine in COVID-19 Vaccines in 1,500 participants. Status unknown.
1 June 2022
Quick facts
| Lead sponsor | Karamanoğlu Mehmetbey University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,500 |
| Start date | 1 June 2021 |
| Primary completion | 1 June 2022 |
| Estimated completion | 1 June 2022 |
| Sites | 4 locations across Turkey (Türkiye) |
Drugs / interventions tested
- Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine — full drug profile →
Conditions studied
- COVID-19 Vaccines — all drugs for COVID-19 Vaccines →
Sponsor
Karamanoğlu Mehmetbey University
Who can join
Adults 18 to 99, any sex, with COVID-19 Vaccines. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study Population Population with vaccinated with three different Covid Vaccines (Inactive Vaccine (Sinovac Life Sciences, Beijing, China), recombinant human adenovirus serotype number 26 (rAd26 of Sputnik V), mRNA Vaccine (Pfizer/BionTEC). This is multi center study, 5 centers will be joined to study from different part of the country. Approximately 1500 people will be enrolled to study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04895007
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19 Vaccines
Currently open trials in the same condition.
- NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
- NCT05556720 — Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Contro · Phase 3 · active not recruiting
- NCT05096260 — Getting to Yes, Michigan! (G2YMI) · NA · active not recruiting
Other Karamanoğlu Mehmetbey University trials
Trials by the same sponsor.
- NCT07499297 — THE EFFECTS OF CIRCADIAN RHYTHM-BASED PROGRESSIVE RELAXATION EXERCISES IN HEMODIALYSIS PATIENTS · NA · not yet recruiting
- NCT07406607 — The Effect of Presence of Father in the Operating Room on Quality of Recovery of the Parturient · NA · recruiting
- NCT07302282 — The Effectiveness of Pain Neuroscience Education for Patients With Carpal Tunnel Syndrome · NA · recruiting
- NCT07377851 — Carbonic Anhydrase II Responses to Basketball-Specific High-Intensity Interval Training · NA · completed
- NCT07142577 — The Effect of Mandala Coloring on Mental Well-Being and Life Satisfaction in Elderly Individuals in Nursing Homes · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04895007 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Karamanoğlu Mehmetbey University
- Last refreshed: 15 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04895007.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing